Anti-D Immunoglobulin Market Revenue to Attain USD 5.3 Bn by 2033

16 Jun 2025

Share :

Table of Content

1. Anti-D Immunoglobulin Market Revenue and Trends 2025 to 2033 2. Market Overview 3. Segment Outlook 4. Regional insights 5. Anti-D Immunoglobulin Market Coverage 6. Anti-D Immunoglobulin Market Key Players

Anti-D Immunoglobulin Market Revenue and Trends 2025 to 2033

The global anti-D immunoglobulin market revenue surpassed USD 3.42 billion in 2025 and is predicted to attain around USD 5.3 billion by 2033, growing at a CAGR of 5.53%. The growth of the market is attributed to the increased awareness of Rh incompatibility, increasing birth rates, and rising demand for combination therapies.

Market Overview

The anti-D immunoglobulin market is experiencing significant growth due to the rising prevalence of Rh incompatibility in pregnant women. This medication is used to prevent Rh incompatibility in pregnant women, which significantly reduces the risk of hemolytic disease of the fetus and newborn (HDFN). In addition, the increasing birth rates around the world, specifically in emerging economies, are significantly raising the demand for preventative options like Anti-D immunoglobulin to support maternal health. The therapeutic indication for anti-D immunoglobulin is also broadening, with the rise of autoimmune diseases and their increasing off-label use for conditions such as immune thrombocytopenic purpura (ITP).

Segment Outlook

• By product, the intravenous anti-D immunoglobulin segment led the market, capturing a major share in 2024. This is mainly due to the increased preference for injectables due to their rapid absorption and targeted delivery, conveniently created dosage form, and proven efficacy, making them suitable for use in Rh prophylaxis.
• By application, the Rh immunoprophylaxis during pregnancy segment held the largest share of the market in 2024. The increased prevalence of Rh-negative pregnant women bolstered the segmental growth. Increasing awareness about Rh incompatibility and guidelines to improve maternal healthcare further drives the growth of the segment.
• By dosage form, the liquid formulation segment led the market with a major share in 2024. The segment’s dominance is reinforced due to the high preference for injections for their rapid onset of action and quick absorption as compared to others.
• By end-user, the hospitals segment accounted for the largest revenue share in 2024 since childbirth mostly happens in the hospital environment. The easy accessibility to specialized prenatal care, including screening procedures, has increased the patient pool in these settings, boosting the demand for anti-D immunoglobulin.
• By route of administration, the intravenous administration segment dominated the market in 2024. This is mainly due to the rising demand for targeted drug delivery. IV is the preferred route due to its clinical effectiveness, safety, ease of administration, and less or no side effects.

Regional insights

North America dominated the anti-D immunoglobulin market with the biggest revenue share in 2024. This is mainly due to the presence of well-established healthcare infrastructure and prenatal care procedures. The increased prevalence of NFD, along with rising birth rates, further supports the regional market. Meanwhile, Asia Pacific is expected to grow at the fastest rate due to the growing increasing birth rates, improvements in maternal healthcare, and governmental programs supporting infants’ health.

Anti-D Immunoglobulin Market Coverage

 Recent Developments

• In December 2024, BSV launched an awareness campaign "Voice of Africa" in the African countries to create awareness on HDFN. This, in turn, boosts the need for ant-D immunoglobulin, a standard medicine for preventing Rh disease.

Anti-D Immunoglobulin Market Key Players

• Octapharma
• Kedrion Biopharma
• Grifols
• Saol Therapeutics
• Bayer
• Bio Products Laboratory
• Others

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/6223

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com|+1 804 441 9344